First pass assay results from Ancasti lithium project.


Published 08-MAR-2017 13:13 P.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Latin Resources (ASX:LRS) has received the first analysis results from reverse circulation drilling at its Ancasti lithium project in Catamarca, Argentina.

At Reflejos del Mar in the Villisman group of concessions 14 holes have been completed over a length of approximately 900 metres. News released today related to samples of the first six holes which included 7 metres grading 2.17% lithium oxide.

All six holes had lithium grades in excess of 1%, and in three of the six, grades of up to 3 metres at 2.77% were recorded.

Management noted that five holes at Ipizca II intercepted the pegmatite dyke that is exposed at surface and within an old open pit and tunnel system, but only one interval returned significant grades of lithium oxide.

Drilling is nearing completion at Campo el Abra where eight holes have been drilled, and results are expected before the end of March.

The drill rig is moving to Santa Gertrudis this week where it will continue the first-pass program, the aim of which is to provide initial information on four of the eleven quality pegmatites that make up the Ancasti lithium project.

Summarising recent and upcoming developments, Managing Director Chris Gale said, “These first assays are extremely encouraging displaying high-grade spodumene at depth and this result is once again proving our theory that the historical lithium mines that we have secured are potentially very economic”.

It should be noted here that LRS is an early stage play and investors considering this stock for their portfolio should seek professional financial advice.

From a broader perspective, Gale also highlighted the fact that as well as getting off to a strong start, there is a significant amount of drilling to complete and a lot more assay results to come from LRS’s favoured targets.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free